Stoke Therapeutics, Inc. STOK Zorevunersen — Operating Expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s zorevunersen — operating expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s zorevunersen — operating expenses?
- Stoke Therapeutics, Inc. (STOK) reported zorevunersen — operating expenses of -$19.85M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s zorevunersen — operating expenses changed year-over-year?
- Stoke Therapeutics, Inc.'s zorevunersen — operating expenses decreased by 12.3% year-over-year, from -$17.67M to -$19.85M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s zorevunersen — operating expenses?
- Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s zorevunersen — operating expenses has grown at a 60.2% compound annual growth rate (CAGR), from -$27.99M to -$71.83M.
- What does zorevunersen — operating expenses mean?
- This metric represents the total costs directly attributable to the research, development, and clinical advancement of the specific therapeutic candidate. It captures the investment required to progress the asset through clinical trials and regulatory milestones. Monitoring these expenses helps investors assess the capital intensity and resource allocation dedicated to this specific pipeline program.